# Safety Study of COVID19 Vaccine on the Market

> **NCT05890521** · PHASE4 · UNKNOWN · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 100000 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant new coronavirus vaccine (CHO cell)

## Key facts

- **NCT ID:** NCT05890521
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-02
- **Primary completion:** 2022-06-16
- **Final completion:** 2023-06
- **Target enrollment:** 100000 (ESTIMATED)
- **Last updated:** 2023-06-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05890521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05890521, "Safety Study of COVID19 Vaccine on the Market". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05890521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*